康缘药业(600557.SH)：收到运脾化痰通窍颗粒临床试验批准通知书

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) has received the clinical trial approval notice from the National Medical Products Administration for its product, Yunpihua Phlegm-Resolving Granules, aimed at treating adenoid hypertrophy in children [1] Group 1: Product Details - Yunpihua Phlegm-Resolving Granules are indicated for the treatment of adenoid hypertrophy with spleen deficiency and phlegm obstruction in children, presenting symptoms such as snoring during sleep, mouth breathing, prolonged nasal congestion, nasal itching, fatigue, poor appetite, and irregular bowel movements [1] - Preclinical efficacy studies show that the granules have a significant therapeutic effect on adenoid hypertrophy, reducing the size of nasal lymph nodes and lymphoid tissue in model animals, and lowering serum inflammatory factors IL-1β, IL-4, MIP-3α, and IL-17A levels [1] - Toxicological studies indicate that the granules have good safety profiles with a wide safety dosage range [1]